Inner ear therapeutics and the war on hearing loss: systemic barriers to success

Frontiers in Neuroscience

Neuroscience

Nicole T. Jiam¹  Steven D. Rauch² 

[1] Department of Otolaryngology – Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear, Boston, MA, United States;null;

关键词: inner ear;    therapeutics;    hearing restoration;    hearing loss;    drug development;   

DOI  :  10.3389/fnins.2023.1169122

 received in 2023-02-18, accepted in 2023-06-02,  发布年份 2023

来源: Frontiers

【 摘 要 】

Despite over 20 years of effort in academic research centers, start-up companies, and established pharmaceutical companies, there are no FDA-approved inner ear therapeutics for treatment of sensorineural hearing loss. There are a number of systemic barriers to creation of this new field of inner ear therapeutics. These include insufficient understanding of the particularity of different causes of hearing loss at the cellular and molecular level, lack of diagnostics of adequate sensitivity and specificity to discern these differences in vivo, a tendency for start-up biotech/pharma companies to prioritize competition over collaboration, and a drug development ecosystem that is really in the “pre-competitive” phase and a lack of infrastructure to develop, validate, gain regulatory approval, and successfully market an inner ear therapeutic. These issues will be discussed in this perspective article and a proposed remedy in the form of an inner ear therapeutics “moon shot” will be offered.

【 授权许可】

Unknown   
Copyright © 2023 Jiam and Rauch.